Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
Market Outlook | Analyst price targets average $130, reflecting optimism for ARE's long-term prospects in the evolving life sciences real estate landscape |
Strategic Development | Delve into Alexandria's 7.0 million square feet development pipeline, with over half pre-leased, showcasing continued demand for high-quality assets |
Financial Resilience | Explore ARE's solid financial performance, with Core FFO meeting expectations and a robust balance sheet, despite near-term industry headwinds |
Life Sciences Leade | Alexandria Real Estate Equities, a top REIT in life sciences properties, navigates market challenges while positioning for long-term growth in prime locations |
Metrics to compare | ARE | Sector Sector - Average of metrics from a broad group of related Real Estate sector companies | Relationship RelationshipAREPeersSector | |
---|---|---|---|---|
P/E Ratio | 43.5x | 33.5x | 8.2x | |
PEG Ratio | 0.18 | 0.72 | 0.01 | |
Price / Book | 0.8x | 2.0x | 0.9x | |
Price / LTM Sales | 4.3x | 8.7x | 3.5x | |
Upside (Analyst Target) | 46.8% | 12.9% | 20.8% | |
Fair Value Upside | Unlock | −3.9% | 3.5% | Unlock |